CN Patent

CN113164450A — 用于治疗转移性前列腺癌的组合治疗

Assigned to Progenics Pharmaceuticals Inc · Expires 2021-07-23 · 5y expired

What this patent protects

本文中提供了用于治疗和/或鉴定针对前列腺癌的治疗可做出响应之患者的组合物和相关方法。

USPTO Abstract

本文中提供了用于治疗和/或鉴定针对前列腺癌的治疗可做出响应之患者的组合物和相关方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN113164450A
Jurisdiction: CN
Classification: —
Expires: 2021-07-23
Drug substance claim: No
Drug product claim: No
Assignee: Progenics Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.